Curated News
By: NewsRamp Editorial Staff
June 22, 2026
Knight Therapeutics Repays $60M Credit Facility, Bolsters Balance Sheet
TLDR
- Knight Therapeutics repaid $60M debt early, strengthening its balance sheet and freeing cash for future acquisitions.
- Knight used operational cash flow from Canada and Latin America to fully repay its revolving credit facility.
- By repaying debt, Knight improves financial health, enabling continued access to medicines across the Americas.
- Knight's credit facility remains undrawn with $100M capacity plus $100M accordion for growth.
Impact - Why it Matters
This news matters because it demonstrates Knight Therapeutics' strong cash flow generation and financial discipline, which can reassure investors about the company's ability to manage debt and fund future growth. The repayment of the credit facility used for the Paladin acquisition signals operational success and a healthy balance sheet, potentially leading to increased investor confidence and stock performance. For shareholders and potential investors, this indicates that Knight is well-positioned to pursue further expansion in the pharmaceutical sector without over-leveraging.
Summary
Knight Therapeutics Inc. (TSX: GUD) has announced the full repayment of its revolving credit facility with National Bank of Canada and syndicate lenders, a significant milestone following its strategic acquisition of Paladin. The company had drawn $60 million from the facility in June 2025 to finance the acquisition, but has now repaid the entire amount using strong cash flow generated from its operations in Canada and Latin America. This repayment underscores Knight's robust financial health and operational efficiency across its pan-American pharmaceutical business.
The revolving credit facility remains active, providing Knight with up to US$100 million in borrowing capacity, plus an additional US$100 million accordion feature subject to certain conditions. This available liquidity supports the company's ongoing growth strategy as it continues to expand its footprint in the pharmaceutical market. Knight Therapeutics, headquartered in Montreal, Canada, specializes in acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM.
For more details, the full press release is available at https://ibn.fm/8eluB. Knight's shares trade on the TSX under the symbol GUD, and additional company information can be found at www.knighttx.com. The announcement was disseminated via InvestorWire, a specialized communications platform that delivers press release syndication and corporate communications solutions, as part of the IBN's Dynamic Brand Portfolio.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Knight Therapeutics Repays $60M Credit Facility, Bolsters Balance Sheet
